Physician profile
Rupesh Raina
NPI 1295939734
$162,728.42
in general payments reported to CMS, 2019-2025
20 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $34K · 2021: $47K · 2022: $7,724 · 2023: $1,943 · 2024: $3,575 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,750 · Food and Beverage: $1,014 · Education: $11.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,750.00 |
| Food and Beverage | $1,014.16 |
| Education | $11.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $60,108.53 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $43,644.69 | 2020-2024 | Terlivaz, Acthar |
| Mallinckrodt Enterprises LLC | $29,111.44 | 2019 | |
| Aurinia Pharma U.S., INC. | $13,241.99 | 2021-2022 | |
| Horizon Therapeutics Plc | $6,687.56 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,400.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $3,309.24 | 2024 | |
| Kaneka Medical America LLC | $1,500.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $593.31 | 2019-2023 | Farxiga |
| Travere Therapeutics, INC. | $353.96 | 2023-2025 | |
| Glaxosmithkline, LLC. | $224.38 | 2022-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $179.93 | 2019-2024 | Velphoro |
| Vifor Pharma, INC. | $168.62 | 2019-2020 | |
| Inspire Medical Systems, INC. | $94.34 | 2025 | Inspire |
| Amgen INC. | $55.41 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2021 | |
| Calliditas Therapeutics US INC. | $17.95 | 2022 | |
| Nuwellis, INC. | $17.30 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupesh Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.